Long-term clinical outcomes of a novel IOL design for femtosecond laser-assisted cataract surgery

Session Details

Session Title: New IOLs: Material & Preload IOL

Session Date/Time: Monday 24/09/2018 | 08:00-10:30

Paper Time: 09:24

Venue: Room A3, Podium 2

First Author: : S.Shah UK

Co Author(s): :    R. Gil-Cazorla   S. Naroo                 

Abstract Details

Purpose:

To evaluate the long-term results of a novel intraocular lens (IOL) specifically designed for femtosecond laser cataract surgery technology.

Setting:

Midland Eye, Solihull, UK and Aston University, Birmingham, UK

Methods:

The Femtis IOL is a new IOL which has been designed to be clipped to the opening of a capsulotomy created with a femtosecond laser to decrease decentration, tilt and rotation of the lens. In this prospective study, 40 eyes of 20 patients with cataract that had femtosecond laser phacoemulsification with implantation of a Femtis IOL were included. Over a 12-month follow-up period, the main outcome measures were uncorrected and corrected distance visual acuities (UDVA and CDVA, respectively), spherical equivalent (SE) refraction, tilt, torsion, decentration and capsular posterior opacification (CPO) grading.

Results:

At the 12-month follow-up visit, mean UDVA was 0.055 ± 0.148 logMAR (range: 0.5 to -0.2 logMAR) and mean CDVA was -0.058 ± 0.088 logMAR (range: 0.20 to -0.20 logMAR). UDVA was 0.3 logMAR or better in 38 (95%) eyes and 0.1 logMAR or better in 31 (77.5%) eyes. Mean SE refraction was 0.375 ± 0.365 D (range: 1.37 to -0.875 D), with 33 (82.5%) eyes within ±0.50 D of the attempted correction. Tilt, torsion and decentration was lower than that published for any other lens. Mean CPO was not significant in any eye.

Conclusions:

The Femtis laser IOL provided good long-term visual outcomes and predictable refractive results. Lenses designed to be used with femtosecond laser are likely to be an important area of development in the future especially for premium lenses.

Financial Disclosure:

... receives consulting fees, retainer, or contract payments from a company producing, developing or supplying the product or procedure presented, ... travel has been funded, fully or partially, by a competing company, ... travel has been funded, fully or partially, by a company producing, developing or supplying the product or procedure presented, ... research is funded, fully or partially, by a competing company, ... research is funded, fully or partially, by a company producing, developing or supplying the product or procedure presented, ... receives consulting fees, retainer, or contract payments from a competing company